Maven Securities’s Prelude Therapeutics PRLD Stock Holding History

Maven Securities’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,091	Closed	-$264K	–	802
2020 Q3	$264K	Buy	+9,091	New	+$257K	0.02%	507

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Maven Securities's PRLD Position: Q4 2020 in Review

Maven Securities sold out of Prelude Therapeutics (PRLD) in Q4 2020, closing a stake of 9,091 shares — an estimated $264K sold.

Maven Securities first reported a position in PRLD in Q3 2020 and held it in 1 quarter. The position peaked at $264K in Q3 2020. 51 funds tracked by Wall St. Rank hold PRLD as of Q4 2020.

Maven Securities reported no remaining Prelude Therapeutics position as of Q4 2020 after selling out during the quarter.
Maven Securities sold 9,091 Prelude Therapeutics shares in Q4 2020, an estimated $264K.
Maven Securities first reported a position in Prelude Therapeutics in Q3 2020 and held it in 1 quarter.
Maven Securities's Prelude Therapeutics position peaked at $264K in Q3 2020.
51 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2020.

Based on Maven Securities's 13F filing for Q4 2020, filed 12 Feb 2021.